High-throughput kinase profiling as a platform for drug discovery (Q37135359)

18 August 2017

1 reference

title

High-throughput kinase profiling as a platform for drug discovery (English)

1 reference

18 August 2017

1 reference

David M Goldstein

1

1 reference

18 August 2017

Nathanael S Gray

series ordinal

2

1 reference

18 August 2017

Patrick P Zarrinkar

series ordinal

3

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Nature Reviews Drug Discovery

18 August 2017

published in

1 reference

18 August 2017

volume

7

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

391-397

1 reference

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

18 August 2017

cites work

1 reference

New approaches to molecular cancer therapeutics

21 January 2018

1 reference

Mechanisms of drug inhibition of signalling molecules

21 January 2018

1 reference

Integrative genomic approaches identify IKBKE as a breast cancer oncogene

21 January 2018

1 reference

Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis

21 January 2018

1 reference

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

21 January 2018

1 reference

PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?

21 January 2018

1 reference

Kinase activity of mutant LRRK2 mediates neuronal toxicity

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

Targeting checkpoint kinase 1 in cancer therapeutics

21 January 2018

1 reference

Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice

21 January 2018

1 reference

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

21 January 2018

1 reference

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity

21 January 2018

1 reference

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding

21 January 2018

1 reference

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity

21 January 2018

1 reference

Roscovitine targets, protein kinases and pyridoxal kinase

21 January 2018

1 reference

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases

21 January 2018

1 reference

Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

An efficient rapid system for profiling the cellular activities of molecular libraries.

21 January 2018

1 reference

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Creating chemical diversity to target protein kinases

21 January 2018

1 reference

Validating cancer drug targets

21 January 2018

1 reference

Systems biology and combination therapy in the quest for clinical efficacy.

21 January 2018

1 reference

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

Why is cancer drug discovery so difficult?

21 January 2018

1 reference

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

Chemogenomic approaches to drug discovery

21 January 2018

1 reference

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

21 January 2018

1 reference

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

Structure and chemical inhibition of the RET tyrosine kinase domain

21 January 2018

1 reference

SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

21 January 2018

1 reference

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

21 January 2018

1 reference

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

Sorafenib in renal cell carcinoma

21 January 2018

1 reference

Proteins, drug targets and the mechanisms they control: the simple truth about complex networks

21 January 2018

1 reference

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

Regulation of mitosis via mitotic kinases: new opportunities for cancer management

21 January 2018

1 reference

Targeting tyrosine kinases in cancer: the second wave

21 January 2018

1 reference

Multitarget tyrosine kinase inhibition: [and the winner is...].

31 March 2020

1 reference

JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications

31 March 2020

1 reference

Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies

31 March 2020

1 reference

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

31 March 2020

1 reference

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

31 March 2020

1 reference

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2541

1 reference

18 August 2017

1 reference